ArticleCellular & molecular immunology2026
Macrophage USP9X attenuates colitis by restricting oncostatin M production via K27-linked deubiquitination of STAT1.
Article in Cellular & molecular immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- USP9X trims STAT1 to curb oncostatin M activity and intestinal inflammation.Cellular & molecular immunology · 2026Article
Corrections and comments
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
Dysregulated posttranslational modifications drive inflammatory bowel disease (IBD) pathogenesis, yet the specific roles of deubiquitinases in intestinal macrophages remain poorly characterized. Here, we identify ubiquitin-specific peptidase 9X (USP9X) as a critical negative regulator of intestinal inflammation. USP9X expression is reduced in UC patients and inversely correlated with disease severity. Myeloid-specific deletion of USP9X exacerbates colitis in both DSS- and TNBS-induced models, whereas its overexpression ameliorates disease. Mechanistically, USP9X interacts with signal transducer and activator of transcription 1 (STAT1) and removes K27-linked polyubiquitin chains from lysine 544. The loss of USP9X enhances STAT1 nuclear translocation and transcriptional activity, resulting in the upregulation of oncostatin M (OSM) expression and exacerbating inflammation. Mutation of STAT1 at K544 attenuated both basal and USP9X knockdown-induced responses. Notably, neutralizing OSM abrogates the exacerbated colitis phenotype in USP9X-deficient mice. These findings define a USP9X-STAT1-OSM axis that connects ubiquitin editing to transcriptional regulation and represents a potential therapeutic target for IBD. USP9X suppresses STAT1 transcriptional activation by editing K27-linked ubiquitination at lysine 544 In wild-type conditions, USP9X removes K27-linked polyubiquitin chains from STAT1 at lysine 544, limiting its nuclear retention and transcriptional activity. In macrophages, loss of USP9X leads to enhanced K27-linked ubiquitination of STAT1, enhanced STAT1 nuclear translocation, and increased STAT1 occupancy at the Osm promoter, resulting in elevated OSM expression. AAV9-mediated USP9X delivery ameliorates intestinal inflammation by restoring USP9X expression. USP9X, ubiquitin-specific peptidase 9X; STAT1, signal transducer and activator of transcription 1; OSM, Oncostatin M. (Created with Biorender).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.